Core Viewpoint - The article discusses the "hospital-pharmacy linkage" model as a significant innovation in chronic disease management, emphasizing its role in connecting healthcare resources and improving patient care in China [1][2][5]. Group 1: Industry Context - The "hospital-pharmacy linkage" model is part of a national pilot project aimed at addressing chronic non-communicable diseases, which account for 88% of total deaths and over 70% of the disease burden in China [1]. - The increasing prevalence of chronic diseases such as hypertension, diabetes, and respiratory conditions highlights the need for effective management strategies, as only 17.2% of diabetes patients show good medication adherence [1][2]. Group 2: Implementation and Impact - Retail pharmacies are becoming crucial in the chronic disease management system, transitioning from traditional drug sellers to health service providers, as outlined in the "Healthy China 2030" plan [2]. - The "hospital-pharmacy linkage" model has expanded from focusing solely on hypertension to include a broader range of chronic diseases, creating diverse innovative practices [3]. - Collaborative efforts between hospitals and pharmacies have led to enhanced training for pharmacists, improved patient education, and better management of chronic diseases through a comprehensive care approach [3][4]. Group 3: Strategic Partnerships - AstraZeneca is actively supporting the "hospital-pharmacy linkage" model, aiming to establish a standardized and professional chronic disease management system that extends care beyond hospital settings [5]. - The company emphasizes the importance of collaboration among various stakeholders to enhance chronic disease management and achieve the goals set forth in the "Healthy China 2030" initiative [5].
2025西普会:阿斯利康支持打造“院店联动”新范式
2 1 Shi Ji Jing Ji Bao Dao·2025-08-16 05:16